Technical Analysis for ACET - Adicet Bio, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Up | Flat |
Historical ACET trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Wide Bands | Range Expansion | 0.00% | |
200 DMA Support | Bullish | 4.39% | |
20 DMA Support | Bullish | 4.39% | |
Wide Bands | Range Expansion | 4.39% | |
Wide Bands | Range Expansion | 0.74% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 1.74% | |
Inside Day | Range Contraction | 1.74% | |
Wide Bands | Range Expansion | 1.74% | |
200 DMA Support | Bullish | 3.80% | |
20 DMA Support | Bullish | 3.80% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time | |
---|---|---|
10 DMA Resistance | about 11 hours ago | |
Up 5% | about 13 hours ago | |
60 Minute Opening Range Breakout | about 13 hours ago | |
Rose Above 10 DMA | about 13 hours ago | |
Rose Above Previous Day's High | about 16 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 04/10/2020
Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Diseases Immune System Antibodies Cancer Immunotherapy Therapies For Cancer Immune Response Chimeric Antigen Receptor Adoptive Cell Transfer Chimeric Antigen Receptor T Cell T Cell Antigen
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Diseases Immune System Antibodies Cancer Immunotherapy Therapies For Cancer Immune Response Chimeric Antigen Receptor Adoptive Cell Transfer Chimeric Antigen Receptor T Cell T Cell Antigen
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 21.7 |
52 Week Low | 6.02 |
Average Volume | 129,202 |
200-Day Moving Average | 14.37 |
50-Day Moving Average | 14.16 |
20-Day Moving Average | 14.56 |
10-Day Moving Average | 16.39 |
Average True Range | 1.38 |
ADX | 19.95 |
+DI | 24.35 |
-DI | 21.40 |
Chandelier Exit (Long, 3 ATRs ) | 13.67 |
Chandelier Exit (Short, 3 ATRs ) | 16.18 |
Upper Bollinger Band | 18.36 |
Lower Bollinger Band | 10.75 |
Percent B (%b) | 0.74 |
BandWidth | 52.27 |
MACD Line | 0.76 |
MACD Signal Line | 0.62 |
MACD Histogram | 0.134 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 18.40 | ||||
Resistance 3 (R3) | 18.34 | 17.61 | 18.06 | ||
Resistance 2 (R2) | 17.61 | 17.11 | 17.64 | 17.95 | |
Resistance 1 (R1) | 17.01 | 16.79 | 17.31 | 17.07 | 17.84 |
Pivot Point | 16.28 | 16.28 | 16.44 | 16.31 | 16.28 |
Support 1 (S1) | 15.68 | 15.78 | 15.98 | 15.74 | 14.96 |
Support 2 (S2) | 14.95 | 15.46 | 14.98 | 14.85 | |
Support 3 (S3) | 14.35 | 14.95 | 14.74 | ||
Support 4 (S4) | 14.41 |